Shanghai Medicilon Inc. (688202.SH): In August, the company did not repurchase shares.
On August 31, 2024, Medicilon Inc. (688202.SH) announced that it did not repurchase any shares in August 2024. As of August 31, 2024, the company has repurchased a total of 258,153 shares through the Shanghai Stock Exchange system, accounting for 0.1917% of the total share capital. The highest price at which the shares were repurchased was RMB 32.55 per share, and the lowest price was RMB 26.44 per share. The total amount paid was RMB 7,450,315.99 (excluding stamp duty, transaction fees, and other expenses).
Shanghai Medicilon Inc.: Half-year report for the year 2024.
Shanghai Medicilon Inc.: Summary of Half-Year Report in 2024.
Shanghai Medicilon Inc. (688202.SH): net loss of 70.23 million yuan in the first half of the year, turning losses year-on-year.
On August 19, Gelonhui reported that Shanghai Medicilon Inc. (688202.SH) released its half-year report for 2024. The company's new orders and revenue both declined year-on-year in the first half of 2024. The company achieved revenue of 0.521 billion yuan, a decrease of 40.23% year-on-year. During the reporting period, the company's customer structure was mainly domestic customers, with domestic customer income of 0.331 billion yuan, accounting for 63.66% of the main business income; overseas customer income was 0.189 billion yuan, accounting for 36.34% of the main business income; the net loss was 70.23 million yuan, turning a year-on-year loss. During the reporting period, net income attributable to shareholders of the listed company was not disclosed.
Even With A 27% Surge, Cautious Investors Are Not Rewarding Shanghai Medicilon Inc.'s (SHSE:688202) Performance Completely
Shanghai Medicilon Inc. (688202.SH): Has cumulatively repurchased 0.1917% of the company's shares.
On August 2, Glonhooi reported that up to July 31, 2024, shanghai medicilon inc has repurchased 258,153 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding, accounting for 0.1917% of the total share capital of the company. The highest and lowest repurchase prices were 32.55 yuan/share and 26.44 yuan/share, respectively, and the total amount paid was RMB 7,450,315.99 (excluding transaction costs such as stamp duty and brokerage fees).
Medicilon Y Hengrui Pharma Profundizan La Colaboración Estratégica
Medicilon Et Hengrui Pharma Renforcent Leur Collaboration Stratégique Pour Soutenir L'innovation Dans Les ADC, Les Petits Acides Nucléiques Et Les Médicaments CGT
Shanghai Medicilon (SHSE:688202) Has Debt But No Earnings; Should You Worry?
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Shanghai Medicilon Inc. (688202.SH): The price of experimental monkeys has stabilized recently.
Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor conference that the price of experimental monkeys has stabilized in recent times. The company has actively adopted various measures such as enriching procurement channels, deepening cooperation with experimental animal suppliers, etc. to ensure the company's experimental animals, especially the stable supply of experimental monkeys, can meet the needs of the company's operations.
Shanghai Medicilon Inc. (688202.SH): has put into use a total of more than 0.085 million square meters of R&D office space.
Medicilon (688202.SH) recently stated during a meeting with institutional investors that the company has invested in a total of more than 0.085 million square meters of research and development office space, located in Shanghai Zhangjiang Hi-Tech Park Development, Chuansha Economic Park, Nanhui Medicilon New Drug Innovation Center, Hangzhou Xiaoshan District, and a research and development center in Boston, USA. The main structure of the raised funds project "Drug Discovery and Pharmaceutical Research and Declaration Platform Laboratory Expansion Project" has been fully capped and has been applied for acceptance, and the "Medicilon North Shanghai Biomedical Research and Development Innovation Industry Base Project" has also officially started construction. In the future, it will be in accordance with the company's strategy.
Shanghai Medicilon Inc. (688202.SH): Currently, the research and development laboratory in Boston, USA has been put into use.
Shanghai Medicilon Inc. (688202.SH) recently stated during a reception with institutional investors that the company's overseas business development and production operations are actively and orderly underway. The company will lay out in multiple core overseas regions, strengthen the construction of its business team, increase communication between its overseas BD and domestic research teams, and gradually establish a market sales system adapted to overseas market competition. In addition, the company will actively participate in overseas industry conferences and increase the frequency of regular expansion of its research team. Currently, the company has put into use a research and development laboratory in Boston, USA, covering chemical, biological, and animal experiments.
Shanghai Medicilon Inc. (688202.SH) has repurchased 0.1917% of its shares.
On July 1st, Gelonhui reported that Shanghai Medicilon Inc. (688202.SH) has repurchased a total of 258,153 shares through the Shanghai Stock Exchange centralized bidding trading system as of June 30, 2024. The repurchased shares account for 0.1917% of the company's total share capital. The highest repurchase transaction price is 32.55 yuan/share, the lowest is 26.44 yuan/share, and the total amount paid is 7,450,315.99 yuan (excluding stamp duty, transaction fees, and other expenses).
Shanghai medicilon inc. (688202.SH): has repurchased 26,400 shares of company stock.
On June 4th, Gelonhui reported that Shanghai Medicilon Inc. (688202.SH) has cumulatively repurchased 26,353 shares of the company's stock through the Shanghai Stock Exchange auction trading system as of May 31, 2024, accounting for 0.0196% of the total outstanding shares. The highest and lowest repurchase prices were 32.55 yuan/share and 32.44 yuan/share, respectively. The total amount paid was RMB 857,100.20 (excluding stamp duty, transaction fees, and other expenses).
Medici (688202.SH): Initial repurchase of 26,353 shares
Gelonghui (688202.SH) announced on May 30, 2024, that on May 30, 2024, the company repurchased 26,353 shares for the first time through centralized bidding. The repurchased shares accounted for 0.0196% of the company's total share capital, the highest transaction price was 32.55 yuan/share, the minimum transaction price was 32.44 yuan/share, and the total transaction amount was 857,100.20 yuan (excluding transaction fees such as stamp duty and transaction commissions).
Individual Investors Are Shanghai Medicilon Inc.'s (SHSE:688202) Biggest Owners and Were Hit After Market Cap Dropped CN¥385m
Medici (688202.SH): The repurchase period has expired and 745,200 shares have actually been repurchased
Gelonghui, May 13, 丨 Medici (688202.SH) announced that as of May 12, 2024, the company's share repurchase period has expired. The implementation of the share repurchase plan has been completed. 745,166 shares of the company's shares have been actually repurchased through the Shanghai Stock Exchange trading system, accounting for 0.5533% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share. The lowest price was 34.90 yuan/share, the average repurchase price was 53.66 yuan/share, and the total amount of capital paid was RMB 53.66 per share 39,982,446.20 yuan (excluding stamp duty)
Medici (688202.SH): Accumulated cost of 378.75 million yuan to buy back 0.5136% of the shares
On May 7, GLONGHUI (688202.SH) announced that in April 2024, the company had repurchased a total of 84,412 shares of the company through centralized bidding transactions, accounting for 0.0627% of the company's total share capital. The highest price of the repurchase transaction was 35.48 yuan/share, the lowest price was 34.90 yuan/share, and the total capital paid was 2,976,090.07 yuan (excluding transaction fees such as stamp duty and transaction commissions). As of April 30, 2024, the company has repurchased a total of 691 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system.
Medici (688202.SH) reported first-quarter results with a net loss of 375.5557 million yuan
Medici (688202.SH) released its report for the first quarter of 2024, achieving revenue of 260 million yuan, with...
No Data
No Data